India’s Biocon to retain milestone payments from Pfizer deal

MUMBAI (Reuters) – India’s Biocon Ltd will retain milestone payments it received from Pfizer Inc as part of a deal that allowed the U.S. drugmaker to sell Biocon’s insulin products globally, Biocon’s chairman said, without providing details. Certain additional payments would also come from Pfizer, Kiran Mazumdar Shaw told CNBC-TV18 on Tuesday. “This (additional) income will get reflected in our quarterly numbers,” she said, declining to give details. …